Current status of pancreatic cancer diagnosis
Authors:
Tomáš Krechler 1; Josef Hořejš 2; Jan Ulrych 3; Miroslav Zeman 1; Jaroslav Macášek 1; Jaroslava Dušková 4; Aleš Žák 1
Authors place of work:
Univerzita Karlova v Praze, 1. lékařská fakulta, IV. interní klinika VFN
1; Univerzita Karlova v Praze, 1. lékařská fakulta, Radiodiagnostická klinika VFN
2; Univerzita Karlova v Praze, 1. lékařská fakulta, I. chirurgická klinika VFN
3; Univerzita Karlova v Praze, 1. lékařská fakulta, Ústav patologie
4
Published in the journal:
Čas. Lék. čes. 2011; 150: 587-593
Category:
Review Articles
Summary
Pancreatic cancer still remains one of the tumors with the worst prognosis. The five-year survival rate ranges between 0.4 to 2 per cent. In most cases the tumor is diagnosed at an advanced stage, which does not allow a radical surgical treatment. Currently, the diagnosis of pancreatic cancer is based on dynamically developing imaging methods that allow detecting even small lesions. The basic testing method is the contrast computed tomography which is, in most cases, linked up to the endoscopic ultrasonography. In most patients results of the cytopathological and histological examinations are obtained before surgical or oncological therapy. The decisive factor for further therapeutic approach is the tumor staging. Despite the apparent progress in diagnostic techniques, the early diagnosis of pancreatic cancer remains unsatisfactory.
Key words:
pancreatic cancer, imaging methods, computed tomography, endoscopic ultrasonography.
Zdroje
1. Ryska M, Bělina F, Strnad R. Chirurgická terapie. In: Zavoral M. Karcinom pankreatu. Praha: Galén 2005; 167–216.
2. Yeo CJ, Cameron JL. Improving results of pancreaticoduodenectomy for pancreatic cancer. World J Surg 1999; 23: 907–912.
3. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 5–27.
4. Zavoral M. Klinický obraz a diagnostika. In: Zavoral M. Karcinom pankreatu. Praha: Galén 2005; 99–136.
5. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician 2006; 73: 485–492.
6. Yamaguchi K, Tahala M, and Committee for revision of clinical guidelines for pancreatic cancer of Japan Pancreas Society. EBM-based clinical guidelines for pancreatic cancer 2009 from the Japan Pancreas Society: A synopsis. Jpn J Clin Oncol 2011; 41: 836–840.
7. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. JAMA 1995; 273: 1605–1609.
8. Huxley R, Ansary-Moghaddam A, Berrington DF, et al. Type-II – diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076–2083.
9. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer – associated diabetes mellitus. Gastroenterology 2008; 134: 981–987.
10. Tsuchia R, Noda T, Harada N, et al. Colective review of small carcinoma of the pancreas. Ann Surg 1986; 203: 77–81.
11. Krechler T, Zeman M, Vecka M, et al. Karcinom pankreatu – naše zkušenosti se vztahem k diabetes mellitus. Čas Lék čes 2010; 149: 291–296.
12. Dítě P, Trna J, Bělohrádková J, et al. Pancreatic cancer – association with diabetes mellitus and smoking. Vnitř Lék 2011; 57: 159–162.
13. Dítě P, Novotný J, Přecechtělová M, et al. Incidence of pancreatic carcinoma in patiens with chronic pankreatitis. Hepatogastroenterology 2010; 57: 957–960.
14. Koudová M, Macek jr. M. Hereditární pankreatitida a karcinom pankreatu. In: Zavoral M. Karcinom pankreatu. Praha: Galén 2005; 53–65.
15. Greenhalf W, Malates N, Nilsson M, et al. International registries of families at high risk of pancreatic cancer. Pancreatology 2008; 8: 558–565.
16. Buchler MW, Uhl W, Malfertheimer P. Pankreaserkrankungen. Basel: Karger 1996.
17. DiMagno EP, Reber HA, Tempero MA. AGA technical rewiew on the epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999; 177: 1464–1484.
18. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13560 patients with pancreatic cancer and incidence of the diseases in the West Midlands: an epidomiological study. Br J Surg 1995; 82: 111–115.
19. Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer 1995; 76: 1671–1677.
20. Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001; 38: 105–112.
21. Papanikolaou IS, Karatzas PS, Trintafyllou K, et al. Role of endoscopic ultrasonography in 2010. World J Gastroenterol 2010; 2: 335–343.
22. Papanikolaou IS, Adler A, Neumann U, et al. Endoscopic ultrasound in pancreatic disease – its influence on surgical decision-making. Pancreatology 2009; 9: 55–65.
23. Hunt GC, Faigel DO. Assassment of EUS for diagnosing, staging and determinig resectability of pancreatic cancer: a review. Gastrointest Endosc 2002; 55: 323–237.
24. Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol 2004; 182: 619–623.
25. Kim T, Murakami T, Takamura M, et al. Pancreatic mass due to chronic pancreatitis: correlation of CT a MR imaging features aith pathologic findings. AJR Am J Roentgenol 2001; 177: 367–371.
26. Roche CJ, Highes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patents sith ductal adenocarcinoma of the head of pancreas. AJR Am J Roentgenol 2003; 180: 475–480.
27. Adamek HE, Albert J, Breer H, et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356: 190–193.
28. Pamuklar E, Semelka RC. MR imaging of the pancreas. Magn Reson Imaging Clin N Am 2005; 13: 313–330.
29. Janssen J. EUS elastography: current status and perspectives. Z Gastroenterol 2008; 46: 572–579.
30. Itokawa F, Itoi T, Sofuni A, et al. EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. J Gastroenterol 2011; 46: 843–853.
31. Paganuzzi M, Onetto M, Martini P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic biliary diseases. Cancer 1988, 61: 2100–2108.
32. Riker A, Libutti SK, Bartlets DL. Advences in the early detection, diagnosis and staging of pancreatic cancer. Surg Oncol 1997; 6: 157–169.
33. Urban D, Catane R. Serum tumor markers in oncology. Isr Med Assoc J 2009; 12: 103–104.
34. Lee MX, Saif MW. Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP. J Pancreas 2009; 10: 104–108.
35. Kuno N, Kurimoto K, Fukushima M, et al. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a propective study in multiinstitutions. Pancreas 1994; 9: 725–730.
36. Louhimo J, Alfthan H, Stenman UH, Haglund C. Serum HCG beta and CA 72–4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004; 66: 126–131.
37. Okusaka T, Yamada T, Maekawa M. Serum tumor markers for pancreatic cancer: The Dawn of New Era? JOP. J Pancreas 2006; 7: 332–336.
38. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. Pancreatology 2008; 8: 110–1125.
39. Parker LA, Porta M, Lumbreras B, et al. Clinical validity of detecting K–ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. Eur J Epidemiol 2011; 26: 229–236.
40. Kamisawa T, Takuma K, Tabata T, et al. Long-term follow-up of chronic pancreatitis patiens with K-ras mutation in the pancreatic juice. Hepatogastroenterology 2011; 58: 174–176.
41. Krechler T, Jáchymová M, Pavliková M, et al. Polymorphism –23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study. Neoplasma 2009; 56: 26–32.
42. Krechler T, Jáchymová M, Mestek O, et al. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 2010; 43: 882–886.
43. Krechler T, Zeman M, Vecka M, et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma 2011; 58: 58–64.
44. Mansfield JC, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. GUT 1997; 40: 671–677.
45. Jallwala J, Fogel EL, Herman S, et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastroinest Endosc 2000; 51: 383–390.
46. Macken E, Drijkoningen M, Van Aken E, Van Steenbergen W. Brush cytology of ductal strictures during ERCP. Acta Gastroenterol Belg 2000; 63: 254–259.
47. Harewood GC, Wiersems LM, Halling AC, et al. Influence of EUS training and pathology interpretation of accuracy of EUS-guided fine needle aspiration of pancreatic masses. Gastrointest Endosc 2002; 55: 669–673.
48. Raut CP, Braun AM, Staerkel GA, et al. Diagnostic accuracy of endioscopic ultrasound – guided fine-needle aspiration in patiens with presumed pancreatic cancer. J Gastrointest Surg 2003; 7: 118–126.
49. O’Toole D, Palazzo L, Arotcarena R, et al. Assessment of complications of EUS – guided fine-needle aspiration. Gastrointest Endsosc 2001; 53: 470–474.
50. Wilson JL, Kalade A, Prasat S, et al. Diagnosis of solid pancreatic masses by endoscopic ultrasound-guided fine-needle aspiration. Intern Med J 2009; 39: 32–37.
51. Kliment M., Urban O., Cegan M. et al. Endoscopic ultrasound – guided fine needle aspiration of pancreatic masses: the utility and impact on management of patients. Scand J Gastroenterol 2010; 45: 1372–1379.
52. Qian X, Hecht JL. Pancreatic fine needle aspiration. A comparison of computed tomographic and endsoscopic ultrasonographic guidance. Acta Cytol 2003; 47: 723–726.
53. Mallery JS, Centano BA, Hahn PF, et al. Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity. Gastrointest Endosc 2002; 56: 218–224.
54. Chang KJ, Nguyen P, Ericsson RA, et al. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc 1997; 45: 387–393.
55. Michl P, Oauls S, Gross TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 120: 227–251.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Current status of pancreatic cancer diagnosis
- Postoperative recurrence of Crohn’s disease
- The role of estrogens in regulations of biological processes involved into wound healing – a review
- Babyboxes in the Czech Republic – what next?